Previous 10 | Next 10 |
2024-01-24 07:25:27 ET More on Theratechnologies Theratechnologies stock slides as Egrifta review runs beyond FDA target date Upcoming FDA Decision: How likely is approval for EGRIFTA MDV? Seeking Alpha’s Quant Rating on Theratechnologies Historical ea...
FDA requesting clarifications around chemistry, manufacturing and controls and additional information related to immunogenicity CRL does not impact commercial availability of EGRIFTA SV ® , the F4 formulation of tesamorelin, the only medication approved in the U.S. ...
2024-01-23 08:25:53 ET More on Pre-market losers & stocks. Mesoblast Has Major Hurdles Holding The Fort: Mesoblast's Path Towards Overcoming FDA Rejection Mesoblast rises after cell therapy gets FDA rare pediatric disease designation MSP Recovery stock tu...
2024-01-23 08:17:43 ET Shares of Canadian biopharma firm Theratechnologies ( NASDAQ: THTX ) plunged 30% premarket on Tuesday after the U.S. health regulator said it will continue reviewing the supplemental license application for the company's F8 formulation of tesamorelin beyon...
FDA continues to review the file past the Prescription Drug User Fee Act goal date of January 22, 2024 MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company ...
2024-01-19 11:01:06 ET Company: Theratechnologies Inc. (THTX) Seeking Alpha Quant rating for THTX: Hold Wall Street Analysts’ Rating: Buy Seeking FDA Approval for EGRIFTA MDV, which is the F8 formulation of tesamorelin. Type of Application: Supplemental ...
2024-01-02 10:47:47 ET This %Pharmaceutical company is addressing the medical needs of patients with HIV and may be starting the new year off right. %Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovat...
Trogarzo ® IM maintenance dosing aims to further enhance the convenience of non-oral therapy for heavily treatment-experienced adults with HIV Submission comes on the heels of the recent FDA approval of the Trogarzo ® IV push loading dose MONTREAL...
2023-12-21 16:15:57 ET More on Theratechnologies Theratechnologies announces FDA nod of Trogarzo 90-second intravenous push loading dose Theratechnologies prices its public offering; shares plummet For further details see: Theratechnologies files for $100M mixed ...
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement Canada NewsWire MONTREAL , Dec. 21, 2023 /CNW/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company ...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...